Neuroinflammation as a Therapeutic Target for Mitigating the Long-Term Consequences of Acute Organophosphate

Peter M Andrew1, Pamela J Lein1

  • 1Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, United States.

Insights

Organophosphate (OP) poisoning causes seizures and severe outcomes. Targeting neuroinflammation after OP-induced status epilepticus (SE) may prevent chronic neurological damage, but current strategies show inconsistent results.

Area of Science:

  • Neuroscience
  • Toxicology
  • Pharmacology

Background:

  • Acute organophosphate (OP) intoxication can lead to a cholinergic crisis, seizures, and status epilepticus (SE).
  • Current treatments improve survival but fail to prevent chronic neurological deficits like cognitive impairment and epilepsy.
  • Neuroinflammation is implicated in the long-term neurological damage following OP exposure.

Purpose of the Study:

  • To review the progression of neuroinflammation after acute OP intoxication and SE.
  • To examine therapeutic strategies targeting neuroinflammation in OP-induced SE.
  • To identify reasons for inconsistent outcomes and suggest future research directions.

Main Methods:

  • Literature review summarizing existing research on OP intoxication, SE, and neuroinflammation.
  • Comparative analysis of neuroinflammatory responses in OP-induced SE and other SE models.
  • Discussion of studies investigating anti-neuroinflammatory treatments post-OP-induced SE.

Main Results:

  • Neuroinflammation is a key factor in the chronic neurological sequelae of OP intoxication.
  • Targeting neuroinflammation has shown inconsistent and only partial efficacy in mitigating long-term outcomes.
  • The timing and specific pathways of neuroinflammation likely influence therapeutic effectiveness.

Conclusions:

  • Neuroinflammation plays a critical role in the chronic neurological damage following organophosphate poisoning.
  • Current therapeutic interventions targeting neuroinflammation are insufficient for complete neuroprotection.
  • Future strategies should focus on precisely timed and pathway-specific neuroinflammation modulation for better outcomes.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.2K
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.1K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.2K
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.0K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.2K